With a growing number of preclinical studies demonstrating the role of TGF-β in suppressing immune response in different tumor types, more clinical trials have been conducted recently to evaluate the therapeutic safety and efficacy of targeting TGF-β in advanced cancer patients (73, 161). The gene discussed is TGFB1; the disease is neoplasm.